Mayo Clinic Precure - Prospective Study

NCT07332598 | Enrolling By Invitation

• 1 other identifier: 25-005869
• Study Type: observational
• Target: 100,000
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to 1) better understand and predict biological processes before disease begins or is identified, 2) study genomic and environmental contributors to disease, 3) identify ways to stop disease advancement before it becomes serious or complex, and 4) identify potential targets for disease therapy. Participants will be asked to:

• collect biological samples,
• download a mobile app,
• collect speech (voice) recordings, and
• complete surveys

Conditions

Genetic Predisposition; Exposure, Environmental

Outcome Measures

Primary Outcomes (1)

• Build a comprehensive, multi-omics and phenotype dataset

  Up to 5 years

Study Arms (2)

Suspected Genetic Predisposition or Multi-Omics Contribution

Patients with a diagnosis or phenotype with the potential for association with a genetic predisposition or Multi-Omics Contribution

Health Control

Patients with no diagnosis associated with a genetic predisposition or Multi-Omics Contribution.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Mayo Clinic patients

You may qualify if:

• Age ≥ 18 years
• Registered Mayo Clinic patient
• Able to provide informed written consent
• Able to receive mail and packages within a United States (US) state
• Able to collect and ship samples within a US state via FedEx for overnight delivery

You may not qualify if:

• Active hematological cancer or history of a hematological cancer
• Allogeneic Bone Marrow Transplant (autologous bone marrow transplant recipients are acceptable if collected at least one month after transplant)
• Other co-morbidity that, in physician's opinion, would interfere with patient's ability to participate in the study (e.g., reduced ability to comprehend, i.e., dementia, intellectual disability, etc.)

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Related Publications (3)

• Thomas DC. High-volume "-omics" technologies and the future of molecular epidemiology. Epidemiology. 2006 Sep;17(5):490-1. doi: 10.1097/01.ede.0000229950.29674.68. No abstract available.

  PMID: 16906051 BACKGROUND

• Ramos RG, Olden K. Gene-environment interactions in the development of complex disease phenotypes. Int J Environ Res Public Health. 2008 Mar;5(1):4-11. doi: 10.3390/ijerph5010004.

  PMID: 18441400 BACKGROUND

• Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1847-50. doi: 10.1158/1055-9965.EPI-05-0456. No abstract available.

  PMID: 16103423 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Saliva, stool, urine, blood.

MeSH Terms

Conditions

Genetic Predisposition to Disease

Condition Hierarchy (Ancestors)

Disease Susceptibility; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Konstantinos N. Lazaridis, M.D.

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Executive Director, Center for Individualized Medicine

Study Record Dates

• First Submitted: December 30, 2025
• First Posted: January 12, 2026
• Study Start: January 19, 2026
• Primary Completion (Estimated): December 1, 2030
• Study Completion (Estimated): December 1, 2035
• Last Updated: March 16, 2026

Record last verified: 2026-02

Locations

US (1)